Pirtobrutinib in Richter Transformation: Updated Efficacy and Safety Results with 18-Month Median Survival Follow-up from the Phase 1/2 BRUIN Study
Year: 2023
Type: conference-abstract
Source: Blood
Authors: William G. Wierda, Nirav N. Shah, Chan Yoon Cheah, David Lewis, Marc S. Hoffmann, Catherine C. Coombs, Nicole Lamanna, Shuo Ma, Deepa Jagadeesh, Talha Munir, Yucai Wang, Toby A. Eyre, Joanna M. Rhodes, Matthew McKinney, Ewa Lech-Maranda, Constantine S. Tam, Wojciech Jurczak, Koji Izutsu, Alvaro J. Alencar, Manish Patel, John F. Seymour, Jennifer A. Woyach, Lindsey E. Roeker, Philip A. Thompson, Paolo Abada, Caleb Ho, Narasimha Marella, Chunxiao Wang, Amy S. Ruppert, Binoj Chandrasekharan Nair, Hui Liu, Donald E. Tsai, Paolo Ghia
Institutions: The University of Texas MD Anderson Cancer Center, Medical College of Wisconsin, The University of Western Australia, Sir Charles Gairdner Hospital, University Hospitals Plymouth NHS Trust, University of Kansas Medical Center, University of California, Irvine, Herbert Irving Comprehensive Cancer Center, Columbia University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Cleveland Clinic, St James's University Hospital, Mayo Clinic, Churchill Hospital, Rutgers Cancer Institute, Duke Cancer Institute, Instytut Hematologii i Transfuzjologi, The Alfred Hospital, Monash University, The Maria Sklodowska-Curie National Research Institute of Oncology, National Cancer Centre Japan, University of Miami, Sylvester Comprehensive Cancer Center, The Royal Melbourne Hospital, The University of Melbourne, Peter MacCallum Cancer Centre, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Memorial Sloan Kettering Cancer Center, Eli Lilly (United States), Vita-Salute San Raffaele University, IRCCS Ospedale San Raffaele
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4389243226